Приказ основних података о документу
Disturbed Plasma Lipidomic Profiles in Females with Diffuse Large B-Cell Lymphoma: A Pilot Study
dc.creator | Masnikosa, Romana | |
dc.creator | Pirić, David | |
dc.creator | Post, Julia Maria | |
dc.creator | Cvetković, Zorica | |
dc.creator | Petrović, Snježana | |
dc.creator | Paunović, Marija | |
dc.creator | Vučić, Vesna | |
dc.creator | Bindila, Laura | |
dc.date.accessioned | 2023-09-11T09:35:49Z | |
dc.date.available | 2023-09-11T09:35:49Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | http://rimi.imi.bg.ac.rs/handle/123456789/1340 | |
dc.description.abstract | Lipidome dysregulation is a hallmark of cancer and inflammation. The global plasma lipidome and sub-lipidome of inflammatory pathways have not been reported in diffuse large B-cell lymphoma (DLBCL). In a pilot study of plasma lipid variation in female DLBCL patients and BMI-matched disease-free controls, we performed targeted lipidomics using LC-MRM to quantify lipid mediators of inflammation and immunity, and those known or hypothesised to be involved in cancer progression: sphingolipids, resolvin D1, arachidonic acid (AA)-derived oxylipins, such as hydroxyeicosatetraenoic acids (HETEs) and dihydroxyeicosatrienoic acids, along with their membrane structural precursors. We report on the role of the eicosanoids in the separation of DLBCL from controls, along with lysophosphatidylinositol LPI 20:4, implying notable changes in lipid metabolic and/or signalling pathways, particularly pertaining to AA lipoxygenase pathway and glycerophospholipid remodelling in the cell membrane. We suggest here the set of S1P, SM 36:1, SM 34:1 and PI 34:1 as DLBCL lipid signatures which could serve as a basis for the prospective validation in larger DLBCL cohorts. Additionally, untargeted lipidomics indicates a substantial change in the overall lipid metabolism in DLBCL. The plasma lipid profiling of DLBCL patients helps to better understand the specific lipid dysregulations and pathways in this cancer. | |
dc.language | en | |
dc.relation | Clinical Lipidomics Unit’s Core Facility at the Institute of Physiological Chemistry, University Medical Centre Mainz | |
dc.relation | Germany Research Society grant number Bl 1399/2-1 | |
dc.relation | info:eu-repo/grantAgreement/MESTD/inst-2020/200017/RS// | |
dc.relation | MBF-funded DIASyM, grant number 031 L0217 | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Cancers | |
dc.source | Cancers | |
dc.subject | DLBCL | |
dc.subject | plasma 4D lipidomics | |
dc.subject | eicosanoids | |
dc.subject | HETEs | |
dc.subject | glycerophospholipids | |
dc.subject | sphingosine 1-phosphate | |
dc.subject | sphingolipids | |
dc.subject | targeted LC-MS | |
dc.subject | tims-Tof | |
dc.title | Disturbed Plasma Lipidomic Profiles in Females with Diffuse Large B-Cell Lymphoma: A Pilot Study | |
dc.type | article | en |
dc.rights.license | BY | |
dc.citation.issue | 14 | |
dc.citation.spage | 3653 | |
dc.citation.volume | 15 | |
dc.identifier.doi | 10.3390/cancers15143653 | |
dc.identifier.fulltext | http://rimi.imi.bg.ac.rs/bitstream/id/3074/Disturbed_Plasma_Lipidomic_Profiles_in_Females_with_Diffuse_pub_2023.pdf | |
dc.type.version | publishedVersion |